These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22829507)

  • 21. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
    Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twelve-month clinical outcomes after coronary stenting with the Genous Bio-engineered R Stent in patients with a bifurcation lesion: from the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) registry.
    Beijk MA; Damman P; Klomp M; Woudstra P; Silber S; Grisold M; Ribeiro EE; Suryapranata H; Wójcik J; Sim KH; Tijssen JG; de Winter AR;
    Coron Artery Dis; 2012 May; 23(3):201-7. PubMed ID: 22487946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of left main coronary trifurcation lesions with the paclitaxel drug-eluting stent: mid-term outcomes from a tertiary medical center.
    Shammas NW; Shammas GA; Jerin M; Parikh A; Coin K; Dippel E; Sharis P; Robken J
    J Invasive Cardiol; 2009 Jul; 21(7):321-5. PubMed ID: 19571341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirolimus- versus paclitaxel-eluting stents for coronary bifurcations intervention: a meta-analysis of five clinical trials.
    Qian J; Chen Z; Ma J; Ge J
    Catheter Cardiovasc Interv; 2012 Oct; 80(4):507-13. PubMed ID: 22045690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcome of patients with de novo coronary bifurcation lesions treated with the Tryton Side Branch Stent. The SAFE-TRY prospective multicenter single arm study.
    Tarantini G; La Vecchia L; Galli M; Favero L; D'Amico G; Buja P; Russo F; Cabianca E; Napodano M; Musumeci G; Franceschini E; Grassi G; Pavei A; Bonmassari R; Cernetti C; Spedicato L; Caprioglio F; Reimers B; Isabella G
    Int J Cardiol; 2013 Oct; 168(6):5323-8. PubMed ID: 24007969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
    Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of stents for small coronary arteries. Results of the Multi-Link 2.5 Portuguese Registry.
    Seabra-Gomes R; Farto eAbreu P; Marques AL; Pereira H; da Cunha JA; Carvalho H; Ribeiro VG; Garcia LM; Mourão L; dos Santos LP; Providência L; Figueiredo L; Almeida M; Cavaco D
    Rev Port Cardiol; 2001 Sep; 20(9):819-37. PubMed ID: 11763595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One-year outcomes with the Taxus Liberté stent in the real world: the Taxus Olympia registry (phase I).
    Ahmed WH; Zambahari R; Al-Rashdan I; Al Naeemi A; Saeed FA; Mascioli S
    J Interv Cardiol; 2008 Dec; 21(6):512-8. PubMed ID: 18973513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Procedural and early clinical outcomes of patients with de novo coronary bifurcation lesions treated with the novel Nile PAX dedicated bifurcation polymer-free paclitaxel coated stents: results from the prospective, multicentre, non-randomised BIPAX clinical trial.
    Costa RA; Abizaid A; Abizaid AS; Garcia del Blanco B; Berland J; Petrov I; Brenot P; van Guens RJ; Royer T; Rubino P; Lesiak M; Fajadet J;
    EuroIntervention; 2012 Mar; 7(11):1301-9. PubMed ID: 22433193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.
    Beijk MA; Klomp M; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; Tijssen JG; Piek JJ; de Winter RJ
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):189-95. PubMed ID: 21542109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM® stent: the randomised, multicentre, open-label, controlled POLBOS II trial.
    Gil RJ; Bil J; Grundeken MJ; Kern A; Iñigo Garcia LA; Vassilev D; Pawłowski T; Formuszewicz R; Dobrzycki S; Wykrzykowska JJ; Serruys PW
    EuroIntervention; 2016 Dec; 12(11):e1404-e1412. PubMed ID: 26600564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies.
    Gil RJ; Bil J; Kern A; Iñigo-Garcia LA; Formuszewicz R; Dobrzycki S; Vassilev D; Mehran R
    Cardiovasc Ther; 2020; 2020():6760205. PubMed ID: 32411301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-Year outcomes after utilization of the TAXUS paclitaxel-eluting stent in bifurcations and multivessel stenting in the ARRIVE registries.
    Brilakis ES; Lasala JM; Cox DA; Bowman TS; Starzyk RM; Dawkins KD
    J Interv Cardiol; 2011 Aug; 24(4):342-50. PubMed ID: 21492221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry.
    Jensen LO; Tilsted HH; Thayssen P; Kaltoft A; Maeng M; Lassen JF; Hansen KN; Madsen M; Ravkilde J; Johnsen SP; Sørensen HT; Thuesen L
    EuroIntervention; 2010 Apr; 5(8):898-905. PubMed ID: 20542774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR).
    Mieres J; Fernandez-Pereira C; Risau G; Solorzano L; Pauletto R; Rodriguez-Granillo AM; Rubilar B; Stella P; Rodriguez AE
    Cardiovasc Revasc Med; 2012; 13(5):265-71. PubMed ID: 22796496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dedicated bifurcation stents or regular drug eluting stents in distal left main stenosis: A retrospective study.
    Kern A; Gil RJ; Bojko K; Rzeszowski B; Bednarski K; Górny J; Bil J
    Cardiol J; 2018; 25(2):188-195. PubMed ID: 28714525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial.
    Kang WC; Ahn T; Lee K; Han SH; Shin EK; Jeong MH; Yoon JH; Park JS; Bae JH; Hur SH; Rha SW; Oh SK; Kim DI; Jang Y; Choi JW; Kim BO
    EuroIntervention; 2011 Dec; 7(8):936-43. PubMed ID: 21959255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.